EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieRandomisierte kontrollierte Studie

Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus+Letrozole: insights from the MIRACLE trial

Xuemin Xue, Danyang Ji, Liyan Xue, Yujing Tan, Bingzhi Wang, Jiayu Wang, Fei Ma, Yang Luo, Bo Lan, Shanshan Chen, Jianming Ying, Binghe Xu und 1 weitere

Cancer Letters · 2026

DOI: 10.1016/j.canlet.2026.218327 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Letters, 2026. Verfasst von Xuemin Xue und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & P…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Drug Resistance, Neoplasm, Everolimus. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Cancer Hospital Chinese Academy of Medical Sciences, CAMS Innovation Fund for Medical Sciences, Beijing Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is the most commonly diagnosed cancer in women globally. Our previous MIRACLE trial (NCT02313051) demonstrated that everolimus plus letrozole (E + L) significantly improves progression-free survival compared with letrozole (L) monotherapy in premenopausal patients with endocrine therapy-resistant, hormone receptor-positive, HER2-non-amplified advanced breast cancer. This study aims to investigate spatially resolved biomarkers linked to survival benefits from E + L to guide precision therapies. Patients from MIRACLE were stratified by overall survival (OS ≤ 3 vs. >3 years). Spatial Whole Transcriptome Atlas analysis was used to evaluate tumor-, immune-, and stroma-specific gene expression, co-expression network patterns, and survival correlations. Among patients with shorter survival (OS ≤ 3 years), we identified a distinctive gene interaction network characterized by tumor-derived S100A9 and CALML5, which is associated with mTORC1 activation. This finding suggests that tasquinimod, an S100A9 inhibitor, could be a viable therapeutic option. Additionally, an interaction between CALML5 and SLPI across tumor and immune areas indicated a potential role in maintaining tumor integrity and mitigating immune-mediated damage. Conversely, patients with longer survival (OS > 3 years) exhibited SERPINA1 as a hub gene linked to estrogen receptor activation, and an interaction between FKBP5 and SESN3 associated with AKT/mTORC1 inhibition within tumor-rich regions. Furthermore, the interaction between MMP11 and COL16A1 in stroma-rich regions suggests that cancer-associated fibroblasts may contribute to improved outcomes. Our study underscores the critical role of spatial gene expression analysis in elucidating the tumor microenvironment and its impact on prognosis in patients undergoing E + L treatment, thereby opening new avenues for targeted interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsDrug Resistance, NeoplasmEverolimusLetrozoleFemaleHumansMiddle AgedBiomarkers, TumorGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksSpatial TranscriptomicsTranscriptomeTumor Microenvironment

Stichwörter der Autor:innen

Breast cancerEstrogen receptorEverolimusSpatial transcriptomicsSurvivalmTORC1

Substanzen

Biomarkers, TumorEverolimusLetrozole

Autor:innen und Institutionen

  • Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China.
  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, China. Electronic…

Förderung

  • Cancer Hospital Chinese Academy of Medical Sciences
  • CAMS Innovation Fund for Medical Sciences
  • Beijing Natural Science Foundation

Zitieren

APA

Xue, X., Ji, D., Xue, L., Tan, Y., Wang, B., Wang, J., Ma, F., Luo, Y., Lan, B., Chen, S., Ying, J., Xu, B., & Fan, Y. (2026). Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus+Letrozole: insights from the MIRACLE trial. Cancer Letters. https://doi.org/10.1016/j.canlet.2026.218327

Vancouver

Xue X, Ji D, Xue L, Tan Y, Wang B, Wang J, et al. Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus+Letrozole: insights from the MIRACLE trial. Cancer Letters. 2026. doi:10.1016/j.canlet.2026.218327

BibTeX
@article{Xue2026,
  author = {Xue, Xuemin and Ji, Danyang and Xue, Liyan and Tan, Yujing and Wang, Bingzhi and Wang, Jiayu and Ma, Fei and Luo, Yang and Lan, Bo and Chen, Shanshan and Ying, Jianming and Xu, Binghe and Fan, Ying},
  title = {Spatially resolved transcriptomics identifies tumor-stroma-immune networks and therapeutic targets in endocrine-resistant advanced breast cancer treated with Everolimus+Letrozole: insights from the MIRACLE trial},
  journal = {Cancer Letters},
  year = {2026},
  doi = {10.1016/j.canlet.2026.218327}
}
Kostenlos starten →